Certara (NASDAQ:CERT) Issues FY 2024 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.410-0.460 for the period, compared to the consensus EPS estimate of 0.430. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $390.6 million. Certara also updated its FY24 guidance to $0.41-0.46 EPS.

Certara Stock Up 8.9 %

Shares of CERT stock opened at $15.12 on Friday. Certara has a twelve month low of $11.81 and a twelve month high of $19.87. The stock has a market cap of $2.43 billion, a P/E ratio of -38.77, a P/E/G ratio of 4.93 and a beta of 1.52. The stock has a 50 day moving average of $15.53 and a 200 day moving average of $16.69. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last posted its earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm had revenue of $96.65 million for the quarter, compared to analysts’ expectations of $94.48 million. As a group, sell-side analysts expect that Certara will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on CERT shares. Barclays dropped their target price on Certara from $18.00 to $16.00 and set an equal weight rating on the stock in a research report on Friday, June 28th. JMP Securities restated a market perform rating on shares of Certara in a research report on Wednesday. Finally, KeyCorp decreased their target price on Certara from $23.00 to $20.00 and set an overweight rating on the stock in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Certara presently has an average rating of Hold and an average price target of $19.44.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.